Amandeep Salhotra, MD

Articles

Timing and Candidacy for AlloHSCT in MDS

April 30th 2025

Panelists discuss how the decision to pursue allogeneic hematopoietic stem cell transplantation (alloHSCT) in myelodysplastic syndromes (MDS) is driven by risk stratification, adverse cytogenetic and molecular features, and clinical trajectory, aiming to offer curative therapy to patients with poor prognoses despite potential transplant-related risks.

AlloHSCT in AML: When, Why, and for Whom?

April 30th 2025

Panelists discuss how identifying appropriate candidates for allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute myeloid leukemia (AML) involves evaluating remission status, relapse risk based on cytogenetics and molecular markers, treatment response, and European LeukemiaNet (ELN) risk classification to balance potential benefits against transplant-related risks.

OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

March 1st 2024

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

The Future of Allo-HSCT and Cellular Therapies

February 23rd 2024

Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.

Investigational Allo-HSCT for Advanced Hematologic Malignancies

February 23rd 2024

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

The Role of Allo-HSCT in Higher-Risk MDS

February 16th 2024

Criteria for identifying patients with MDS most likely to benefit from transplant and choosing the optimal donor source and conditioning regimen on a case-by-case basis.

Toxicity Assessment of Precision-Engineered Allo-HSCT

February 16th 2024

Safety and toxicity data from a clinical trial investigating a novel, precision-engineered allo-HSCT conditioning regimen for older patients with high-risk blood cancers.

Transplant in the Elderly Population

February 9th 2024

This session will focus on considerations and outcomes of allo-HSCT specifically among patients over 55 years of age. The panel will discuss how transplant protocols and supportive care measures can be optimized for this population who are at higher risk of comorbidities, toxicity and poor functional status.

Emerging Cellular Therapies in Hematologic Malignancies

February 9th 2024

An overview of promising novel cellular therapies showing efficacy against hematologic cancers in early-phase clinical trials.

Patient Case Studies of GvHD

February 2nd 2024

Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.

Graft-versus-Host Disease Prophylaxis and Management

January 27th 2024

Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.

Clinical Trial Update: CTN Trial

January 27th 2024

Summarize ongoing and recently completed clinical trials related to allo-HSCT and associated therapies.

Transplant Complications and Survival Outcomes

January 19th 2024

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant

January 19th 2024

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT

January 19th 2024

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

Role of Allogeneic Transplants in Hematologic Malignancies

December 15th 2023

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

Dr. Amandeep Salhotra on the Efficacy and Safety of Orca-Q in GVHD

February 24th 2023

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.